Kite’s CAR T-cell Therapy Helps Aggressive Lymphoma Patients, Clinical Trial Shows – Lymphoma News Today
Lymphoma News Today |
Kite's CAR T-cell Therapy Helps Aggressive Lymphoma Patients, Clinical Trial Shows
Lymphoma News Today Eighty-two percent of patients with refractory aggressive lymphoma have responded to Kite Pharma's KTE-C19 chimeric antigen receptor (CAR) T-cell therapy, and 36 percent have achieved complete remission, according to preliminary results of a clinical … |
